诺和诺德豪掷2亿美元,押注口服减重小分子,与Septerna共拓多靶点代谢新药版图

动脉网
17 May

诺和诺德与Septerna达成合作协议,以2亿美元预付款获取口服小分子药物全球开发与商业化权利,意在与礼来在口服代谢药物市场上竞争,这些药物可靶向GLP-1、GIP和胰高血糖素等热门靶点,标志着诺和诺德在口服多靶点疗法方向的战略前移。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10